Unternehmen Bristol-Myers Squibb Company Swiss Exchange

Unternehmen Bristol-Myers Squibb Company Swiss Exchange

850501

US1101221083

BMY

Pharmazeutika

Analystenschätzungen

Aktien

850501

US1101221083

BMY

Pharmazeutika

Analystenschätzungen

Kurzporträt

Umsatz nach Geschäftsbereich

Umsatz je Region

Manager

Aufsichtsräte

Anteilsklasse

Aktionäre

Unternehmensbesitz

Unternehmenskontakt

Konzerngesellschaften

Sektor

Umsatz je Region

Ratings für Bristol-Myers Squibb Company

Verlauf des Gewinns je Aktie

Quartalsgewinne - Abweichungsrate

Sektor Pharmazeutika - Andere

Kurzporträt

Umsatz nach Geschäftsbereich

Umsatz je Region

Manager

Aufsichtsräte

Anteilsklasse

Aktionäre

Unternehmensbesitz

Unternehmenskontakt

Konzerngesellschaften

Sektor

Umsatz je Region

Ratings für Bristol-Myers Squibb Company

Verlauf des Gewinns je Aktie

Quartalsgewinne - Abweichungsrate

Sektor Pharmazeutika - Andere

Markt geschlossen - Swiss Exchange Andere Börsenplätze 17:35:20 28.06.2019			% 5 Tage	% 1. Jan.
44,39 ^CHF	-0,25 %		-18,16 %	-18,16 %

16.05.	Bristol-Myers Squibb erhält beschleunigte FDA-Zulassung für Breyanzi bei follikulärem Lymphom	MT
16.05.	Bristol Myers Squibb's CAR T-Zelltherapie Breyanzi von der U.S. Food and Drug Administration für rezidiviertes oder refraktäres follikuläres Lymphom zugelassen	CI

Bristol-Myers Squibb Company ist auf die Entwicklung, Herstellung und Vermarktung von pharmazeutischen Produkten spezialisiert. Die Produkte sind für die Behandlung von Krebs, Herz-Kreislauf-Erkrankungen, Lebererkrankungen, Immunkrankheiten und psychiatrischen Erkrankungen bestimmt.
Die Vereinigten Staaten machen 70,1% des Nettoumsatzes aus.

Mitarbeiterzahl: 34 100

USD in Millionen	2022	Gewichtung	2023	Gewichtung	Delta
Innovative Medicines 100,0 %	46 159	100,0 %	45 006	100,0 %	-2,50 %

USD in Millionen	2022	Gewichtung	2023	Gewichtung	Delta
United States 70,1 %	31 828	69,0 %	31 555	70,1 %	-0,86 %
International 28,3 %	13 497	29,2 %	12 752	28,3 %	-5,52 %
Other 1,6 %	834	1,8 %	699	1,6 %	-16,19 %

Manager	Titel	Alter	Seit
Christopher Boerner CEO	Chief Executive Officer	53	01.02.15
David Elkins DFI	Director of Finance/CFO	55	20.11.19
Greg Meyers CTO	Chief Tech/Sci/R&D Officer	-	-
Kimberly McCutcheon Jablonski CMP	Compliance Officer	-	01.01.03
Estelle Vester-Blokland CTO	Chief Tech/Sci/R&D Officer	-	-
Samit Hirawat CTO	Chief Tech/Sci/R&D Officer	55	01.01.19
Robert Plenge CTO	Chief Tech/Sci/R&D Officer	53	01.11.19
Laura Hortas IRO	Public Communications Contact	-	-
Cynthia Piccirillo PRN	Corporate Officer/Principal	-	-
Cari Gallman PRN	Corporate Officer/Principal	-	-

Aufsichtsräte	Titel	Alter	Seit
Phyllis Yale BRD	Director/Board Member	66	20.11.19
Peter Arduini BRD	Director/Board Member	59	01.04.16
Derica Rice BRD	Director/Board Member	59	01.09.20
Paula Price BRD	Director/Board Member	62	01.09.20
Theodore Samuels BRD	Director/Board Member	69	21.02.17
David Elkins DFI	Director of Finance/CFO	55	20.11.19
Christopher Boerner CEO	Chief Executive Officer	53	01.02.15
Julia Haller BRD	Director/Board Member	69	20.11.19
Karen Vousden BRD	Director/Board Member	66	01.01.18
Manuel Hidalgo Medina BRD	Director/Board Member	56	01.06.21

	Vote	Menge	Streubesitz	Konzerneigene Aktien	Total Float
Aktie A	1	2 923 100 096	2 024 918 592 ( 69,27 %)	896 000 000 ( 30,65 %)	69,27 %

Name	Aktien	%	Bewertung
Vanguard Fiduciary Trust Co. 9,181 %	186 067 109	9,181 %	8 317 Mio CHF
BlackRock Advisors LLC 6,185 %	125 355 772	6,185 %	5 603 Mio CHF
STATE STREET CORPORATION 4,518 %	91 571 110	4,518 %	4 093 Mio CHF
JPMorgan Investment Management, Inc. 4,368 %	88 525 438	4,368 %	3 957 Mio CHF
Capital Research & Management Co. (International Investors) 3,464 %	70 203 814	3,464 %	3 138 Mio CHF
Charles Schwab Investment Management, Inc. 2,650 %	53 715 966	2,650 %	2 401 Mio CHF
Fidelity Management & Research Co. LLC 2,100 %	42 557 702	2,100 %	1 902 Mio CHF
Geode Capital Management LLC 2,038 %	41 304 605	2,038 %	1 846 Mio CHF
BlackRock Life Ltd. 1,574 %	31 893 511	1,574 %	1 426 Mio CHF
Norges Bank (13F) 1,501 %	30 413 639	1,501 %	1 359 Mio CHF

Name	Aktien	%	Bewertung
Bram Bradesco Asset Management S/A DTVM 0,000233 %	4 731	0,000233 %	209 518 CHF

Name	Aktien	%	Bewertung
Transcend Wealth Collective LLC -	117 775	-	7 184 CHF
FourWorld Capital Management LLC -	100 000	-	6 100 CHF
Davenport & Co. LLC -	83 970	-	5 122 CHF
CapFinancial Partners LLC -	20 498	-	1 250 CHF
FIFTH THIRD BANCORP -	20 000	-	1 220 CHF
Private Advisor Group LLC -	15 000	-	915 CHF
Paradigm Financial Partners LLC -	10 000	-	610 CHF
Northwestern Mutual Wealth Management Co. -	242	-	15 CHF
OAKWORTH CAPITAL INC. -	125	-	8 CHF
Atlantic Edge Private Wealth Management LLC -	16	-	1 CHF

Name	Aktien	%	Bewertung
AVIDITY BIOSCIENCES, INC. 6,37%	5 075 304	6,37%	120 944 494 $
KURA ONCOLOGY, INC. 1,80%	1 370 171	1,80%	26 033 249 $
KURA ONCOLOGY, INC. 6,36%	759 145	6,36%	21 438 255 $
COMPUGEN LTD. 5,31%	4 757 058	5,31%	9 546 749 $
CELULARITY INC. 5,49%	1 195 327	5,49%	3 669 654 $

Bristol Myers Squibb Co.

Route 206 & Province Line Road

08543, Princeton

+609 252 4621

http://www.bms.com

Straße Bristol-Myers Squibb Company(BMY)

Name	Kategorie und Branche
Bristol-Myers Squibb India Pvt Ltd. Bristol-Myers Squibb India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb India Pvt Ltd. discovers, develops and delivers medicines for immuno-oncology. The company is based in Mumbai, India.	Pharmaceuticals: Major
Bristol-Myers Squibb de México S de RL de CV Bristol-Myers Squibb de México S de RL de CV Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb de México S de RL de CV is a Mexican company that manufactures and supplies pharmaceutical and nutritional products. The company is located in Mexico.	Pharmaceuticals: Major
Celgene Kappa Holdings LLC
Bristol-Myers Squibb International Co. ULC
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH
Seamair Insurance DAC
Bristol-Myers Squibb AE
Swords Laboratories Unlimited Co. Swords Laboratories Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Swords Laboratories Unlimited Co. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Swords, Ireland.	Pharmaceuticals: Major
BMS Strategic Portfolio Investments Holdings, Inc.
Bristol-Myers Squibb (Finland) Oy Ab Bristol-Myers Squibb (Finland) Oy Ab Pharmaceuticals: GenericHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb (Finland) Oy Ab is a Finnish pharmaceutical manufacturing company. The company is based in Vantaa, Finland. The company was founded in 1974. Simone Böhrer has been the CEO of the company since 2020.	Pharmaceuticals: Generic
Celgene Alpine Investment Co. LLC
Bristol-Myers Squibb SARL Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France.	Medical Distributors
Celgene Alpine Investment Co. III LLC Celgene Alpine Investment Co. III LLC Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene Alpine Investment Co. III LLC is an American company that provides investment services. The company is located in the US.	Financial Conglomerates
Westwood-Intrafin SA
BMS Forex Co.
Bristol-Myers Squibb GmbH & Co. KGaA Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb GmbH & Co. KGaA is a German company that manufactures biopharmaceutical medicines. The company is based in Munich, Germany. The CEO of the company is Han Steutel.	Pharmaceuticals: Major
Bristol-Myers Squibb SA (Spain)
Bristol-Myers Squibb KK Bristol-Myers Squibb KK BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb KK develops, manufactures and markets biopharmaceutical products. The company is based in Shinjuku-ku, Japan.	Biotechnology
Bristol-Myers Squibb Australia Pty Ltd. Bristol-Myers Squibb Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Australia Pty Ltd. is a biopharmaceutical company that researches, develops and markets medicines for serious diseases. The company was founded in 1930 and is headquartered in Noble Park North, Australia.	Pharmaceuticals: Major
Bristol-Myers Squibb Belgium SA Bristol-Myers Squibb Belgium SA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Belgium SA develops, manufactures and distributes medicines. The company is based in Watermael-Boitsfor, Belgium. The CEO of the Belgian company is Paul Lacante.	Pharmaceuticals: Major
Bristol-Myers Squibb SRL Bristol-Myers Squibb SRL Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb SRL develops, manufactures and supplies pharmaceuticals. It offers diabetes, oncology, cardiovascular, neuroscience, virology, and immunology services. The company is headquartered in Rome, Italy.	Pharmaceuticals: Major
Bristol-Myers Squibb Pharmaceuticals Unlimited Co.
Bristol-Myers Squibb Canada Co. Bristol-Myers Squibb Canada Co. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Canada Co. designs, develops and wholesales pharmaceutical products. The company is headquartered in Halifax, Canada.	Pharmaceuticals: Major
Bristol-Myers Squibb Holdings Ireland Unlimited Co. Bristol-Myers Squibb Holdings Ireland Unlimited Co. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Holdings Ireland Unlimited Co., a subsidiary of Bristol Myers Squibb Co., is a company headquartered in Ireland that operates as a holding company which develops medicines for serious diseases.	Pharmaceuticals: Major
JUNO THERAPEUTICS INC	Biotechnology
Bristol-Myers Squibb Pharmaceuticals Ltd. Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK.	Pharmaceuticals: Major
Bristol-Myers Squibb AB Bristol-Myers Squibb AB Medical DistributorsDistribution Services Part of Bristol Myers Squibb Co., Bristol-Myers Squibb AB is a company that wholesales medical equipment and pharmacy. The company is based in Solna, Sweden.	Medical Distributors
Bristol-Myers Squibb SA (Switzerland)

Trading Rating

Investment Rating

ESG Refinitiv

Mehr Ratings

Verkaufen

Kaufen

Durchschnittl. Empfehlung

HALTEN

Anzahl Analysten

Letzter Schlusskurs

44,11 USD

Mittleres Kursziel

53,19 USD

Abstand / Durchschnittliches Kursziel

+20,60 %

Analystenschätzungen

Entwicklung der Schätzungen

Unternehmenstermine

	% 1. Jan.	Kap.
ELI LILLY AND COMPANY	+32,07 %	694 Mrd.
NOVO NORDISK A/S	+29,39 %	593 Mrd.
JOHNSON & JOHNSON	-1,75 %	371 Mrd.
MERCK & CO., INC.	+19,95 %	331 Mrd.
ABBVIE INC.	+6,87 %	290 Mrd.
ASTRAZENECA PLC	+14,25 %	239 Mrd.
ROCHE HOLDING AG	-3,03 %	209 Mrd.
NOVARTIS AG	+10,02 %	209 Mrd.
AMGEN INC.	+7,93 %	169 Mrd.

Pharmazeutika - Andere

Gesundheitspflege

Pharmazie und Biotechnologie

Pharmazie und Biotechnologie

Pharmazeutika

Pharmazeutika - Andere